Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – May 11, 2022) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the „Company“ or „Innocan“) is pleased to announce that an International Patent Application („PCT“) titled „Protein-bound Cannabinoid Formulations and Uses Thereof“ was recently published and received the publication number WO 2022/070191 (the „Patent Application“), claiming priority from a US provisional application filed in October 2020…